About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Journal of Immunotherapy
›
Top Articles
Journal of Immunotherapy
Oncology
,
Pharmacology
,
Biology
,
Immunology
5
(top 3%)
Impact Factor
5.5
(top 3%)
extended IF
108
(top 3%)
H-Index
958
authors
2.2K
papers
64.5K
citations
3.6K
citing journals
27.6K
citing authors
Most Cited Articles of Journal of Immunotherapy
Title
Year
Citations
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy
2013
758
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma
2010
728
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
2007
564
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients
2003
510
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
2013
393
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b
2010
351
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells
2006
341
Induction of cytokine production from human monocytes stimulated with alginate
1991
314
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma
2001
304
A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma
2002
297
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer
2005
285
PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors
2015
270
Vitiligo in Patients with Melanoma
1996
260
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor
2009
255
Cancer and inflammation: promise for biologic therapy
2010
254
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma
2005
252
Human immune response to monoclonal antibodies
1994
243
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy
2009
235
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine
2011
232
A clinical development paradigm for cancer vaccines and related biologics
2007
225
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
2006
222
Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients
2009
219
Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity
2011
214
Tumor-induced immune dysfunctions caused by myeloid suppressor cells
2001
214
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens
2005
211
previous
2008
2009
2010
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.